[go: up one dir, main page]

IL158771A0 - Pharmaceutical compositions of adsorbates of amorphous drug - Google Patents

Pharmaceutical compositions of adsorbates of amorphous drug

Info

Publication number
IL158771A0
IL158771A0 IL15877102A IL15877102A IL158771A0 IL 158771 A0 IL158771 A0 IL 158771A0 IL 15877102 A IL15877102 A IL 15877102A IL 15877102 A IL15877102 A IL 15877102A IL 158771 A0 IL158771 A0 IL 158771A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
adsorbates
amorphous drug
amorphous
drug
Prior art date
Application number
IL15877102A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23158346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL158771(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL158771A0 publication Critical patent/IL158771A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
IL15877102A 2001-06-22 2002-05-21 Pharmaceutical compositions of adsorbates of amorphous drug IL158771A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30026001P 2001-06-22 2001-06-22
PCT/IB2002/001792 WO2003000238A1 (fr) 2001-06-22 2002-05-21 Compositions pharmaceutiques de produits d'adsorption de medicament amorphe

Publications (1)

Publication Number Publication Date
IL158771A0 true IL158771A0 (en) 2004-05-12

Family

ID=23158346

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15877102A IL158771A0 (en) 2001-06-22 2002-05-21 Pharmaceutical compositions of adsorbates of amorphous drug

Country Status (29)

Country Link
US (3) US20030054037A1 (fr)
EP (2) EP2275091A1 (fr)
JP (1) JP4547148B2 (fr)
KR (2) KR100768766B1 (fr)
CN (1) CN1523979A (fr)
AT (1) ATE486586T1 (fr)
AU (1) AU2002302903B2 (fr)
BG (1) BG108489A (fr)
BR (1) BR0210519A (fr)
CA (1) CA2448825C (fr)
CR (1) CR7167A (fr)
CZ (1) CZ20033456A3 (fr)
DE (1) DE60238193D1 (fr)
EA (1) EA006777B1 (fr)
EC (1) ECSP034895A (fr)
EE (1) EE200400034A (fr)
HU (1) HUP0400281A3 (fr)
IL (1) IL158771A0 (fr)
IS (1) IS7018A (fr)
MA (1) MA27038A1 (fr)
MX (1) MXPA03010165A (fr)
NO (1) NO20035498D0 (fr)
NZ (1) NZ529490A (fr)
OA (1) OA12625A (fr)
PL (1) PL367674A1 (fr)
SK (1) SK15742003A3 (fr)
TN (1) TNSN03138A1 (fr)
WO (1) WO2003000238A1 (fr)
ZA (1) ZA200308735B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371416A1 (en) * 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
CA2474838C (fr) 2002-02-01 2009-01-06 Pfizer Products Inc. Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
WO2005011635A2 (fr) 2003-08-04 2005-02-10 Pfizer Products Inc. Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005023225A1 (fr) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Adsorbat de cilostazol
EP1614412A1 (fr) * 2003-11-18 2006-01-11 Helm AG Procédé pour la préparation d' adsorbats d'atorvastatine pulverulents à écoulement libre
EP1563833B1 (fr) * 2004-02-06 2006-11-02 Helm AG Compositions pharmaceutiques comprenant du tibolone amorphe
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
BRPI0514753A (pt) 2004-08-31 2008-06-24 Pfizer Prod Inc formas de dosagem farmacêutica compreendendo um medicamento de baixa solubilidade e um polìmero
GB2419094A (en) * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
DE102004055229A1 (de) * 2004-11-17 2006-05-18 Heidelberger Druckmaschinen Ag Zustandsabhängige Absicherung von Maschinen
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
CA2605214C (fr) * 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Nouveaux derives de benzylamine en tant qu'inhibiteurs de cetp
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US20090005384A1 (en) * 2005-01-25 2009-01-01 Kowa Co., Ltd Method for Producing Adsorptive Porous Body
PT1855652E (pt) 2005-01-28 2016-01-26 Bend Res Inc Secagem de partículas contendo fármacos
WO2006082518A1 (fr) 2005-02-03 2006-08-10 Pfizer Products Inc. Compositions pharmaceutiques a efficacite amelioree
US20090169583A1 (en) * 2005-02-08 2009-07-02 Pfizer, Inc. Solid Adsorbates of Hydrophobic Drugs
EP1767194A1 (fr) * 2005-06-09 2007-03-28 Helm AG Procédé pour la préparation d'adsorbats de drospirenone
WO2008122048A2 (fr) 2007-04-02 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Elimination d'agents de contraste dans le sang
CA2681829A1 (fr) * 2007-04-03 2008-10-16 Dr. Reddy's Laboratories Ltd. Formes solides de pemetrexed
EP1987816A1 (fr) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate d'un sel de rasagiline en combinaison avec un agent inactive soluble dans l'eau
CA2697099C (fr) 2007-08-21 2018-02-20 Board Of Regents, The University Of Texas System Melange thermocinetique pour des applications pharmaceutiques
EP2072042A1 (fr) * 2007-12-21 2009-06-24 Lek Pharmaceuticals D.D. Ingrédient pharmaceutique actif sur support solide amorphe et avec solubilité améliorée
JP5437232B2 (ja) 2008-03-11 2014-03-12 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
BRPI0912099A2 (pt) * 2008-05-30 2015-10-06 Eisai R&D Man Co Ltd preparação percutaneamente absorvível
CN107320485A (zh) * 2008-10-02 2017-11-07 匹兹堡大学-属高等教育联邦体系 用于治疗全身性炎症的吸附剂聚合物的施用
WO2010050897A1 (fr) * 2008-10-28 2010-05-06 Agency For Science, Technology And Research Excipients en matériau mésoporeux pour ingrédients très peu solubles dans l'eau
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
WO2010092925A1 (fr) * 2009-02-12 2010-08-19 あすか製薬株式会社 Dispersion solide, composition pharmaceutique comprenant celle-ci et procédés de production de la dispersion solide et de la composition pharmaceutique
US8685458B2 (en) * 2009-03-05 2014-04-01 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
EP3130396B1 (fr) 2009-03-27 2021-03-17 Bend Research, Inc. Procédé de séchage par pulvérisation
EP2238979A1 (fr) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Ingrédient pharmaceutique actif absorbé sur un support solide
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
EP2366378A1 (fr) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Formulations de donépézil à libération prolongée
EP2544664A1 (fr) * 2010-03-11 2013-01-16 Danmarks Tekniske Universitet Composés supportés biologiquement actifs
WO2011148253A2 (fr) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Formes posologiques solides d'antipsychotiques
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012031129A2 (fr) 2010-09-03 2012-03-08 Bend Research, Inc. Appareil de séchage par pulvérisation et ses procédés d'utilisation
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
WO2012040502A1 (fr) 2010-09-24 2012-03-29 Bend Research, Inc. Procédé et appareil de séchage par pulvérisation à température élevée
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
AU2012295397A1 (en) * 2011-08-16 2014-02-20 Merck Sharp & Dohme Corp. Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
WO2015118015A1 (fr) * 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Compositions pharmaceutiques solides d'antagonistes du récepteur des androgènes
EP3212169B1 (fr) 2014-10-31 2021-01-13 Bend Research, Inc. Procédé de formation de domaines actifs dispersés dans une matrice
WO2016204058A1 (fr) * 2015-06-15 2016-12-22 住友化学株式会社 Procédé de fabrication d'élément électroluminescent organique
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
JP2023543815A (ja) 2020-09-29 2023-10-18 シェンチェン ファーマシン シーオー．，エルティーディー． 医薬組成物
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用
WO2023179777A1 (fr) 2022-03-25 2023-09-28 Shenzhen Pharmacin Co., Ltd. Compositions pharmaceutiques de composés protac et leurs utilisations
WO2025067450A1 (fr) * 2023-09-28 2025-04-03 福贝生物医药科技(北京)有限公司 Dispersion solide, composition pharmaceutique, et procédé de préparation et utilisation associés

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (fr) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
JPS5942313A (ja) * 1982-09-01 1984-03-08 Teijin Ltd ポリビニルポリピロリドンを用いた製剤
DE3485000D1 (de) * 1983-06-28 1991-10-10 Takeda Chemical Industries Ltd Gemahlene mischung.
US4581232A (en) 1983-07-20 1986-04-08 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4717565A (en) 1986-03-27 1988-01-05 Warner-Lambert Company Process for the preparation of medicament adsorbates
US4711774A (en) 1986-03-27 1987-12-08 Warner-Lambert Company Medicament adsorbates with complex magnesium aluminum silicate and their preparation
US4716033A (en) 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
US5015479A (en) 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4835186A (en) 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
IT1216570B (it) 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IE60458B1 (en) 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5626878A (en) * 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
SI9500059A (sl) 1995-02-23 1996-08-31 Lek Tovarna Farmacevtskih Postopek za pripravo trdnih površinskih disperzij amorfnih, v vodnih medijih slabo topnih učinkovin in njihova uporaba
CA2218173A1 (fr) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogues du facteur liberant l'hormone de croissance
AU6378796A (en) * 1995-06-06 1996-12-24 Warner-Lambert Company Ranitidine salts on magnesium trisilicate as an adsorbate
DE19532061A1 (de) * 1995-08-31 1997-03-06 Bayer Ag N-Sulfonyliminodithioverbindungen
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627419A1 (de) 1996-07-08 1998-01-15 Bayer Ag Cycloalkano-pyridine
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
DE19704243A1 (de) 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US6403587B1 (en) 1997-02-26 2002-06-11 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
EP0901786B1 (fr) * 1997-08-11 2007-06-13 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
WO1999014204A1 (fr) 1997-09-16 1999-03-25 G.D. Searle & Co. 1,2,4-triazoles substitues permettant d'inhiber l'activite proteinique de transfert d'ester de cholesteryle
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19832159A1 (de) 1997-09-18 1999-03-25 Bayer Ag Substituierte Tetrahydro-naphthaline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741400A1 (de) 1997-09-19 1999-03-25 Bayer Ag Benzyl-biphenyle
DE19741399A1 (de) 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
JP2003525839A (ja) * 1997-09-29 2003-09-02 ベイジン・ファイ・チャイニーズ・ファーマスーティカル・ファクトリー 金蕎麦群成物、その製造方法および分析方法並びにその使用
ES2268847T3 (es) 1998-02-05 2007-03-16 Pfizer Products Inc. Nuevos derivados del acido dihidroxihexanoico.
WO1999041237A1 (fr) 1998-02-13 1999-08-19 G.D. Searle & Co. Pyridines substituees utiles pour inhiber l'activite de la proteine assurant le transfert de l'ester de cholesteryle
JPH11246404A (ja) 1998-03-04 1999-09-14 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
US20010025046A1 (en) 1999-06-24 2001-09-27 Rong(Ron) Liu Self-emulsifying systems containing anticancer medicament
EP1104290B1 (fr) * 1998-08-13 2010-03-31 Cima Labs Inc. Microemulsions comme formes pharmaceutiques solides destinees a une administration orale
US6376481B2 (en) 1998-09-02 2002-04-23 Mcneil-Ppc, Inc. Sterol esters in tableted solid dosage forms
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
EP1115694A1 (fr) 1998-09-25 2001-07-18 Monsanto Company Heteroalkylamines tertiaires n-aliphatiques-n-aromatiques substituees, utiles comme inhibiteurs de l'activite de la proteine de transfert de l'ester de cholesteryle
PT1115693E (pt) 1998-09-25 2007-08-02 Monsanto Co Arial- e heteroaril - heteroalquilaminas terciárias policíclicas substituídas úteis para inibir a actividade da proteína de transferência de éster de colesterilo.
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
BR0009177A (pt) * 1999-03-19 2002-01-22 Ranbaxy Lab Ltd Processo para preparação de uma forma de dosagem oral biodisponìvel de axetil cefuroxima
KR100342943B1 (ko) 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
PE20011184A1 (es) * 2000-03-16 2001-11-15 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6602523B1 (en) 2000-08-17 2003-08-05 Technology Holding, Llc. Composite material and process for increasing bioavailability and activity of a beneficial agent
US6596262B2 (en) * 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery

Also Published As

Publication number Publication date
KR20060113801A (ko) 2006-11-02
EP1404302A1 (fr) 2004-04-07
OA12625A (en) 2006-06-12
BR0210519A (pt) 2004-06-22
CR7167A (es) 2004-02-23
WO2003000238A1 (fr) 2003-01-03
SK15742003A3 (sk) 2005-01-03
ATE486586T1 (de) 2010-11-15
IS7018A (is) 2003-11-10
BG108489A (bg) 2004-07-30
AU2002302903B2 (en) 2007-05-17
EP1404302B1 (fr) 2010-11-03
EA200301279A1 (ru) 2004-06-24
NO20035498D0 (no) 2003-12-10
HUP0400281A2 (hu) 2004-08-30
CZ20033456A3 (en) 2004-07-14
PL367674A1 (en) 2005-03-07
US8389006B2 (en) 2013-03-05
KR100759635B1 (ko) 2007-09-17
AU2002302903B9 (en) 2003-01-08
HUP0400281A3 (en) 2009-11-30
ZA200308735B (en) 2004-09-15
EP2275091A1 (fr) 2011-01-19
TNSN03138A1 (fr) 2005-12-23
ECSP034895A (es) 2004-01-28
NZ529490A (en) 2005-08-26
US8703199B2 (en) 2014-04-22
US20080292707A1 (en) 2008-11-27
MXPA03010165A (es) 2004-03-10
EA006777B1 (ru) 2006-04-28
US20030054037A1 (en) 2003-03-20
DE60238193D1 (de) 2010-12-16
CN1523979A (zh) 2004-08-25
CA2448825A1 (fr) 2003-01-03
MA27038A1 (fr) 2004-12-20
EE200400034A (et) 2004-06-15
KR100768766B1 (ko) 2007-10-19
KR20040023632A (ko) 2004-03-18
JP4547148B2 (ja) 2010-09-22
CA2448825C (fr) 2009-08-11
US20070148236A1 (en) 2007-06-28
JP2005501820A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
IL158771A0 (en) Pharmaceutical compositions of adsorbates of amorphous drug
USD484229S1 (en) Air freshener device
WO2005011635A3 (fr) Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
USD495082S1 (en) Lamp with adjustable arm
AU2002360530A1 (en) (5) helicene AND dibenzofluorene MATERIALS FOR USE IN ORGANIC LIGHT EMITTING DEVICES
AU2003277391A1 (en) Semiconductor device with parallel plate trench capacitor
AU2003270019A1 (en) Dental illumination device
CA2395331A1 (fr) Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
AU1889201A (en) Power supply and led lamp device
AU2003220082A1 (en) Thermionic vacuum diode device with adjustable electrodes
AU2002357776A1 (en) Drug implant injection device
AU1904300A (en) Improved organic led device
AU2003276908A1 (en) Absorbent article with containment flaps
AU2002339150A1 (en) Container with organic light emitting device
AU2003286847A1 (en) Solid state inducting device
AU2002352500A1 (en) Absorbent articles with absorbent pad gapping
AU2003292984A1 (en) Amino-substituted oligothiophenes as organic semiconductor materials
AU2003223423A1 (en) Bipolar transistor with graded base layer
AU2003278456A1 (en) Gum base composition
AU2001237455A1 (en) Multi-use heating device for the evaporation of active substances
EP1398497B8 (fr) Inejcteur avec un disque perfore d'injection
AU8007200A (en) Field emission device having surface passivation layer
ATE469902T1 (de) Amorphe substanz eines tricyclischen triazolobenzazepinderivats
AU2001217666A1 (en) Silica-reinforced rubber compounded with an alkoxysilane and a strong organic base
AU2003281004A1 (en) Semiconductor light source device